These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17250464)

  • 1. European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006.
    Schiavon G; Santini D; Vincenzi B; Tonini G
    Expert Opin Biol Ther; 2007 Feb; 7(2):269-78. PubMed ID: 17250464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in solid tumors: monoclonal antibodies and small molecules.
    Weiner LM; Borghaei H
    Hum Antibodies; 2006; 15(3):103-11. PubMed ID: 17065741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular target structures in oncology].
    Spiekermann K; Hiddemann W
    Internist (Berl); 2005 Aug; 46(8):847-8, 850-4, 856-60. PubMed ID: 16007411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
    Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
    Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
    J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Novel Targeted Therapies in Oncology.
    Shah RR; Curigliano G
    Drug Saf; 2019 Feb; 42(2):157-158. PubMed ID: 30649739
    [No Abstract]   [Full Text] [Related]  

  • 12. Liposomal therapies in oncology: does one size fit all?
    Sousa I; Rodrigues F; Prazeres H; Lima RT; Soares P
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):741-755. PubMed ID: 30116847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 17. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
    Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.